Which has better valuation and earnings, AZN or AMGN?

Astrazeneca has higher revenue and earnings than Amgen. Astrazeneca is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.11 $10.23B $6.69 23.29 Amgen $36.75B 5.74 $7.71B $14.37 27.18

Is AZN or AMGN more profitable?

Amgen has a net margin of 20.96% compared to Astrazeneca's net margin of 17.02%. Amgen's return on equity of 137.41% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Amgen 20.96% 137.41% 13.28%

Does the media favor AZN or AMGN?

In the previous week, Amgen had 15 more articles in the media than Astrazeneca. MarketBeat recorded 73 mentions for Amgen and 58 mentions for Astrazeneca. Amgen's average media sentiment score of 0.88 beat Astrazeneca's score of 0.80 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 31 Very Positive mention(s) 5 Positive mention(s) 14 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive Amgen 38 Very Positive mention(s) 13 Positive mention(s) 14 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation and earnings, AZN or BIIB?

Astrazeneca has higher revenue and earnings than Biogen. Astrazeneca is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.11 $10.23B $6.69 23.29 Biogen $9.89B 3.11 $1.29B $5.65 36.89

Is AZN or BIIB more profitable?

Astrazeneca has a net margin of 17.02% compared to Biogen's net margin of 8.32%. Astrazeneca's return on equity of 31.45% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Biogen 8.32% 11.18% 6.88%

Does the media refer more to AZN or BIIB?

In the previous week, Biogen had 6 more articles in the media than Astrazeneca. MarketBeat recorded 64 mentions for Biogen and 58 mentions for Astrazeneca. Biogen's average media sentiment score of 0.93 beat Astrazeneca's score of 0.80 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 31 Very Positive mention(s) 5 Positive mention(s) 14 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive Biogen 33 Very Positive mention(s) 6 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, AZN or MRNA?

Astrazeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.11 $10.23B $6.69 23.29 Moderna $1.94B 11.72 -$2.82B -$7.99 N/A

Is AZN or MRNA more profitable?

Astrazeneca has a net margin of 17.02% compared to Moderna's net margin of -141.43%. Astrazeneca's return on equity of 31.45% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Moderna -141.43% -28.30% -19.39%

Does the media prefer AZN or MRNA?

In the previous week, Moderna had 3 more articles in the media than Astrazeneca. MarketBeat recorded 61 mentions for Moderna and 58 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.80 beat Moderna's score of 0.46 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 31 Very Positive mention(s) 5 Positive mention(s) 14 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive Moderna 18 Very Positive mention(s) 9 Positive mention(s) 13 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, AZN or NVAX?

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.11 $10.23B $6.69 23.29 Novavax $1.12B 1.12 $440.30M -$0.58 N/A

Is AZN or NVAX more profitable?

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -14.73%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Novavax -14.73% -14.82% 1.23%

Does the media refer more to AZN or NVAX?

In the previous week, Astrazeneca had 50 more articles in the media than Novavax. MarketBeat recorded 58 mentions for Astrazeneca and 8 mentions for Novavax. Astrazeneca's average media sentiment score of 0.80 beat Novavax's score of -0.11 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 31 Very Positive mention(s) 5 Positive mention(s) 14 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive Novavax 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, AZN or ABBV?

Astrazeneca has higher earnings, but lower revenue than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.11 $10.23B $6.69 23.29 AbbVie $61.16B 7.04 $4.23B $3.54 68.88

Is AZN or ABBV more profitable?

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% AbbVie 9.80% -466.39% 14.35%

Does the media prefer AZN or ABBV?

In the previous week, AbbVie had 38 more articles in the media than Astrazeneca. MarketBeat recorded 96 mentions for AbbVie and 58 mentions for Astrazeneca. AbbVie's average media sentiment score of 0.85 beat Astrazeneca's score of 0.80 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 31 Very Positive mention(s) 5 Positive mention(s) 14 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive AbbVie 50 Very Positive mention(s) 14 Positive mention(s) 15 Neutral mention(s) 9 Negative mention(s) 2 Very Negative mention(s) Positive

Astrazeneca (AZN) Competitors

$155.79 -2.18 (-1.38%)

Closing price 08/4/2026 03:59 PM Eastern

Extended Trading

$156.32 +0.53 (+0.34%)

As of 04:07 AM Eastern

Compare

AZN vs. AMGN, BIIB, MRNA, NVAX, and ABBV

Should you buy Astrazeneca stock or one of its competitors? MarketBeat compares Astrazeneca with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Astrazeneca include Amgen (AMGN), Biogen (BIIB), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV). These companies are all part of the "healthcare" sector.

How does Astrazeneca compare to Amgen?

Astrazeneca (NYSE:AZN) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

In the previous week, Amgen had 15 more articles in the media than Astrazeneca. MarketBeat recorded 73 mentions for Amgen and 58 mentions for Astrazeneca. Amgen's average media sentiment score of 0.88 beat Astrazeneca's score of 0.80 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	31 Very Positive mention(s)	5 Positive mention(s)	14 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	38 Very Positive mention(s)	13 Positive mention(s)	14 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Astrazeneca has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Astrazeneca currently has a consensus target price of $211.00, indicating a potential upside of 35.44%. Amgen has a consensus target price of $357.00, indicating a potential downside of 8.61%. Given Astrazeneca's stronger consensus rating and higher probable upside, equities research analysts clearly believe Astrazeneca is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43

Astrazeneca has higher revenue and earnings than Amgen. Astrazeneca is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.11	$10.23B	$6.69	23.29
Amgen	$36.75B	5.74	$7.71B	$14.37	27.18

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.6%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Astrazeneca is clearly the better dividend stock, given its higher yield and lower payout ratio.

Amgen has a net margin of 20.96% compared to Astrazeneca's net margin of 17.02%. Amgen's return on equity of 137.41% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Amgen	20.96%	137.41%	13.28%

Summary

Amgen beats Astrazeneca on 13 of the 20 factors compared between the two stocks.

How does Astrazeneca compare to Biogen?

Astrazeneca (NYSE:AZN) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Astrazeneca has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

Astrazeneca currently has a consensus target price of $211.00, indicating a potential upside of 35.44%. Biogen has a consensus target price of $224.61, indicating a potential upside of 7.75%. Given Astrazeneca's stronger consensus rating and higher possible upside, research analysts plainly believe Astrazeneca is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Astrazeneca has a net margin of 17.02% compared to Biogen's net margin of 8.32%. Astrazeneca's return on equity of 31.45% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Biogen	8.32%	11.18%	6.88%

Astrazeneca has higher revenue and earnings than Biogen. Astrazeneca is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.11	$10.23B	$6.69	23.29
Biogen	$9.89B	3.11	$1.29B	$5.65	36.89

In the previous week, Biogen had 6 more articles in the media than Astrazeneca. MarketBeat recorded 64 mentions for Biogen and 58 mentions for Astrazeneca. Biogen's average media sentiment score of 0.93 beat Astrazeneca's score of 0.80 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	31 Very Positive mention(s)	5 Positive mention(s)	14 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive
Biogen	33 Very Positive mention(s)	6 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Astrazeneca beats Biogen on 10 of the 17 factors compared between the two stocks.

How does Astrazeneca compare to Moderna?

Astrazeneca (NYSE:AZN) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Astrazeneca has a net margin of 17.02% compared to Moderna's net margin of -141.43%. Astrazeneca's return on equity of 31.45% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Moderna	-141.43%	-28.30%	-19.39%

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Astrazeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.11	$10.23B	$6.69	23.29
Moderna	$1.94B	11.72	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 3 more articles in the media than Astrazeneca. MarketBeat recorded 61 mentions for Moderna and 58 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.80 beat Moderna's score of 0.46 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	31 Very Positive mention(s)	5 Positive mention(s)	14 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive
Moderna	18 Very Positive mention(s)	9 Positive mention(s)	13 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral

Astrazeneca currently has a consensus target price of $211.00, suggesting a potential upside of 35.44%. Moderna has a consensus target price of $42.13, suggesting a potential downside of 26.18%. Given Astrazeneca's stronger consensus rating and higher probable upside, equities analysts plainly believe Astrazeneca is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88

Astrazeneca has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Summary

Astrazeneca beats Moderna on 11 of the 16 factors compared between the two stocks.

How does Astrazeneca compare to Novavax?

Astrazeneca (NYSE:AZN) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

In the previous week, Astrazeneca had 50 more articles in the media than Novavax. MarketBeat recorded 58 mentions for Astrazeneca and 8 mentions for Novavax. Astrazeneca's average media sentiment score of 0.80 beat Novavax's score of -0.11 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	31 Very Positive mention(s)	5 Positive mention(s)	14 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.11	$10.23B	$6.69	23.29
Novavax	$1.12B	1.12	$440.30M	-$0.58	N/A

Astrazeneca currently has a consensus price target of $211.00, suggesting a potential upside of 35.44%. Novavax has a consensus price target of $13.00, suggesting a potential upside of 69.71%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

Astrazeneca has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Novavax has a beta of 2.46, meaning that its share price is 146% more volatile than the broader market.

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -14.73%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Novavax	-14.73%	-14.82%	1.23%

Summary

Astrazeneca beats Novavax on 12 of the 17 factors compared between the two stocks.

How does Astrazeneca compare to AbbVie?

Astrazeneca (NYSE:AZN) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Astrazeneca presently has a consensus target price of $211.00, suggesting a potential upside of 35.44%. AbbVie has a consensus target price of $272.76, suggesting a potential upside of 11.86%. Given Astrazeneca's higher possible upside, analysts plainly believe Astrazeneca is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84

Astrazeneca has higher earnings, but lower revenue than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.11	$10.23B	$6.69	23.29
AbbVie	$61.16B	7.04	$4.23B	$3.54	68.88

Astrazeneca has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
AbbVie	9.80%	-466.39%	14.35%

In the previous week, AbbVie had 38 more articles in the media than Astrazeneca. MarketBeat recorded 96 mentions for AbbVie and 58 mentions for Astrazeneca. AbbVie's average media sentiment score of 0.85 beat Astrazeneca's score of 0.80 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	31 Very Positive mention(s)	5 Positive mention(s)	14 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive
AbbVie	50 Very Positive mention(s)	14 Positive mention(s)	15 Neutral mention(s)	9 Negative mention(s)	2 Very Negative mention(s)	Positive

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

AbbVie beats Astrazeneca on 14 of the 20 factors compared between the two stocks.

Get Astrazeneca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZN vs. The Competition

Export

Metric	Astrazeneca	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$245.00B	$11.49B	$6.83B	$23.87B
Dividend Yield	2.75%	2.73%	2.59%	3.71%
P/E Ratio	23.29	791.61	279.15	32.20
Price / Sales	4.11	735.50	592.00	20.33
Price / Cash	12.22	71.54	72.11	31.77
Price / Book	4.80	10.83	12.95	6.93
Net Income	$10.23B	$2.81B	$3.48B	$1.07B
7 Day Performance	-10.07%	2.70%	3.40%	2.83%
1 Month Performance	-20.09%	-3.13%	-2.79%	1.75%
1 Year Performance	4.58%	190.97%	73.07%	19.74%

Astrazeneca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZN Astrazeneca	4.7731 of 5 stars	$155.79 -1.4%	$211.00 +35.4%	+4.4%	$245.00B	$58.74B	23.29	96,100	Trending News Options Volume High Trading Volume
AMGN Amgen	3.9589 of 5 stars	$385.16 -0.6%	$357.00 -7.3%	+29.4%	$207.87B	$36.75B	26.80	31,500	Trending News Earnings Report Dividend Announcement
BIIB Biogen	3.8966 of 5 stars	$202.95 -2.4%	$223.36 +10.1%	+57.7%	$29.96B	$9.89B	35.92	7,500	Earnings Report Analyst Forecast
MRNA Moderna	1.5091 of 5 stars	$54.82 -5.4%	$40.00 -27.0%	+106.5%	$21.75B	$2.20B	N/A	4,700	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up
NVAX Novavax	1.8853 of 5 stars	$7.32 -1.6%	$13.00 +77.6%	+13.5%	$1.20B	$596.34M	N/A	1,990	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AZN) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Astrazeneca (AZN) Competitors